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ABSTRACT
Background: Patients with rheumatoid arthritis (RA)
with an inadequate response to TNF antagonists (aTNFs)
may switch to an alternative aTNF or start treatment from
a different class of drugs, such as rituximab (RTX). It
remains unclear in which clinical settings these ther-
apeutic strategies offer most benefit.
Objective: To analyse the effectiveness of RTX versus
alternative aTNFs on RA disease activity in different
subgroups of patients.
Methods: A prospective cohort study of patients with RA
who discontinued at least one aTNF and subsequently
received either RTX or an alternative aTNF, nested within
the Swiss RA registry (SCQM-RA) was carried out. The
primary outcome, longitudinal improvement in 28-joint
count Disease Activity Score (DAS28), was analysed
using multivariate regression models for longitudinal data
and adjusted for potential confounders.
Results: Of the 318 patients with RA included; 155
received RTX and 163 received an alternative aTNF. The
relative benefit of RTX varied with the type of prior aTNF
failure: when the motive for switching was ineffectiveness
to previous aTNFs, the longitudinal improvement in DAS28
was significantly better with RTX than with an alternative
aTNF (p=0.03; at 6 months, 21.34 (95% CI 21.54 to
21.15) vs 20.93 (95% CI 21.28 to 20.59), respec-
tively). When the motive for switching was other causes,
the longitudinal improvement in DAS28 was similar for
RTX and alternative aTNFs (p=0.40). These results were
not significantly modified by the number of previous aTNF
failures, the type of aTNF switches, or the presence of co-
treatment with a disease-modifying antirheumatic drug.
Conclusion: This observational study suggests that in
patients with RA who have stopped a previous aTNF
treatment because of ineffectiveness changing to RTX is
more effective than switching to an alternative aTNF.
Tumour necrosis factor antagonists (aTNFs) are
very effective at improving the symptoms and
signs of rheumatoid arthritis (RA) and at prevent-
ing structural joint damage.
1–4 However, not all
patients with RA respond to aTNFs and about one-
third of all patients with RA fail to achieve even a
modest improvement of 20% in American College
of Rheumatology criteria in large randomised
controlled trials (RCTs).
5 Furthermore, some
patients discontinue aTNF because of adverse
events (AEs) or the development of a secondary
resistance, with gradual loss of effectiveness of
these agents.
6
Until recently, therapeutic options were limited
for patients not responding satisfactorily to an
aTNF. Despite a similar mode of action within the
aTNF class, switching from one aTNF to another
was the established treatment approach for
patients for whom an aTNF failed or who did
not tolerate an initial aTNF.
7 The rationale for
switching between aTNFs resides in variations in
the chemical structure, in pharmacokinetic proper-
ties, in the stability of the TNF inhibitor complex
and in the incidence of drug-neutralising antibodies
between these agents.
8 In patients for whom
etanercept produced an inadequate response, one
small randomised trial suggested a more favourable
response for patients who switched to infliximab
compared with those maintaining treatment with
etanercept.
9 From observational studies, we know
that the effectiveness of subsequent aTNFs differs
according to the reasons for switching.
10–12
Biological agents with a different mechanism of
action have become available, such as interleukin
(IL) 1 inhibitors, IL6 inhibitors, B-cell depleting
antibodies, or inhibitors of T-cell co-stimulation. A
rationale for introducing biological agents with a
different mode of action after a previous aTNF
failure may be to overcome an aTNF class effect,
particularly in cases of primary failure or recur-
rence of class-associated AEs. Several of these
alternative biological agents have proved to be
effective in patients with a history of prior aTNF
failure in large RCTs against placebo.
13–15 However,
head-to-head trials comparing pertinent therapeu-
tic options are missing. Small observational studies
suggested that rituximab (RTX) may be more
effective at controlling disease activity than an
alternative aTNF in a population of patients with
RA with an inadequate response to one or more
aTNF.
16–19 A previous analysis of approximately 100
patients with RA from the Swiss RA cohort
observed a more favourable evolution of 28-joint
count Disease Activity Scores (DAS28) in the
group that received RTX compared with alterna-
tive aTNFs,
16 but the reasons leading to treatment
switches were not examined. Patients may inter-
rupt aTNF therapy for various reasons and it
remains unclear in which clinical setting each
therapeutic strategy offers most benefit.
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switching to an alternative aTNF compared with initiating RTX
in different subgroups of patients. In particular, we studied the
influence on RA disease activity of the reason for switching, the
type of aTNF switch, the number of previous aTNF failures and
the presence of concomitant disease-modifying antirheumatic
drugs (DMARDs).
METHODS
Study population
Swiss Clinical Quality Management in rheumatoid arthritis
(SCQM-RA) is a Swiss RA cohort, which has been described in
detail elsewhere (online supplementary appendix).
20 21 Inclusion
criteria for this analysis were a diagnosis of RA by a
rheumatologist, discontinuation of an aTNF (infliximab,
etanercept or adalimumab) followed by the initiation of either
a second or a third alternative aTNF or a first course of RTX.
We further required a baseline assessment of the DAS28 at the
time of the new treatment initiation and at least one follow-up
assessment within the first 12 months. The only exclusion
criterion was RTX treatment for lymphoma. We censored
observations after aTNF treatment interruption or RTX re-
treatment. The analysis includes data collected between January
1998 and the end of March 2008.
Study design
This was a longitudinal cohort study of patients with RA for
whom at least one previous aTNF had produced an inadequate
response. The study’s predefined primary outcome was the
longitudinal improvement of RA disease activity as measured by
the DAS28, a validated tool for the assessment of disease
activity in RA.
22 We used the DAS28 based on three variables,
including the erythrocyte sedimentation rate, the number of
swollen joints and the number of tender joints.
22 The DAS28
ranges from 0.1 to 9.2, where 9.2 represents maximum disease
activity.
Because the aim of thisstudy was toanalyse the relative benefit
of RTX compared with alternative aTNF in different subgroup of
patients, we selected a priori four potential effect modifiers: the
reason for switching, the type of aTNF switch, the number of
previous aTNF failures, and the presence of co-treatment with
conventional DMARDs (supplementary appendix).
Analysis
Baseline disease and treatment characteristics were compared
between the two groups using the Student t test for normally
distributed variables, the Mann–Whitney U test for non-
normally distributed variables and the Pearson x
2 test for
dichotomous variables. Fewer than 5% of covariates were
sporadically missing; in order to minimise potential bias, we
used the population average of the respective covariates as a
substitute. All statistical tests were evaluated at the 0.05
significance level and were two-sided. Statistical analysis was
performed with Stata version 9.2 (Stata Statistical Software,
Texas, USA).
Since this is an observational study, selection bias is a concern
because treatment assignment of RTX versus an alternative
aTNF is not random. In fact, baseline characteristics suggest
that for rheumatoid factor (RF)-positive patients and patients
for whom an aTNF had been ineffective, treatment was
preferentially started with RTX. Because such differences may
substantially influence the evolution of disease activity, we used
a propensity score approach to overcome such confounding
effects and make the groups comparable for covariates believed
to be associated with disease progression and to minimise the
possibility of confounding by indication (supplementary appen-
dix).
23 The propensity score was used to stratify patients into
five blocks with similar baseline characteristics. The evolution
of disease activity outcomes was analysed using generalised
mixed models for longitudinal data, adjusting for potential
confounding factors using the propensity score stratas and the
potential effect modifiers (supplementary appendix). We
explored potential effect modification by the reason for
switching, the type of aTNF switch, the number of previous
aTNF failures and the presence of concomitant DMARDs using
an interaction term.
RESULTS
Out of a total 479 patients in the SCQM-RA registry who
received RTX or a second or third aTNF, 99 patients (21%) were
excluded because of missing baseline DAS assessment (assess-
ment not on the precise day of treatment switch), 59 patients
(12%) were excluded because of missing follow-up assessments
within the first year and three patients (1%) were excluded
because RTX was administrated for concomitant lymphoma
and not primarily for the treatment of RA. Excluded subjects
were similar in their socioeconomic and disease characteristics
(data not shown).
A total of 318 patients with RA met study inclusion criteria;
155 patients received RTX and 163 patients received a second or
third aTNF. The 318 patients had an average of 3.6 assessments
during a median follow-up period of 11 months (interquartile
range (IQR) 6–12). At baseline, there were some differences
between the RTX and the alternative aTNF groups (table 1).
Patients in the RTX group were more often RF positive, had
higher baseline DAS28 levels, higher Health Assessment
Questionnaire scores and had tried more aTNF agents that
had failed. Differences in baseline disease activity were partially
explained by dissimilar causes of previous aTNF failure: patients
given RTX preferentially after aTNF inefficacy (82% versus
51%, p,0.001), and a history of aTNF inefficacy was
significantly associated with higher baseline DAS levels (4.88
vs 3.83 for other motives of aTNF discontinuation, p,0.001).
After propensity score stratification, all baseline predictors were
balanced, without significant differences between groups. In
particular, no difference in baseline DAS28 levels (p=0.73) or in
RF positivity (p=0.97) remained.
Patients in the RTX group received a single course of RTX (two
infusions of 1000 mg) with concomitant glucocorticoids, accord-
ing to the manufacturer’s indications. In the alternative aTNF
group, 51% of patients received adalimumab 40 mg subcuta-
neously every 2 weeks, 26% received etanercept 50 mg/week and
23% received infliximab intravenously, starting with 3 mg/kg.
The longitudinal improvement in DAS28 was overall more
favourable in the RTX group than in the alternative aTNF
group during the first year (p=0.016). However, the relative
benefit of RTX varied with the cause of prior aTNF failure
(effect modification, p=0.005; (supplementary appendix, table
2)). When the cause for switching was ineffectiveness to a
previous aTNF, the longitudinal improvement in DAS28 was
significantly better for RTX than for an alternative aTNF
(p=0.03; fig 1A). In this subgroup, at 6 months the decrease in
DAS28 was 21.34 (95% CI 21.54 to 21.15) with RTX and
20.93 (95% CI 21.28 to 20.59) with alternative aTNFs. This
represents 61% of patients with RTX compared with 37% with
aTNF who had an improvement in DAS28 of more then 1.2
units, a clinically meaningful difference (p=0.001).
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AE or other reason), the longitudinal improvement in DAS28
was similar for RTX and for alternative aTNFs (p=0.40; fig 1B).
At 6 months the decrease in DAS28 was 20.94 (95% CI 21.37
to 20.52) with RTX and 20.78 (95% CI 21.14 to 20.43) with
alternative aTNFs. The percentage of patients whose DAS28
score improved by more then 1.2 units at 6 months was also
similar in the two groups (39% with RTX vs 28% with an
aTNF, p=0.28). Overall, the magnitude of DAS28 improve-
ments was smaller in patients having switched treatment for
reasons other than ineffectiveness, which is related to lower
baseline DAS28 levels in this subgroup of patients. Patients
experiencing an AE do not necessarily present with an RA flare
at the time of treatment switch and therefore start the new
treatment with lower baseline levels of disease activity, which
results in smaller effect sizes.
When initiating an alternative aTNF, a majority of patients
(68%) switched from an aTNF monoclonal antibody to a TNF
soluble receptor or vice versa. No effect modification by the type
of aTNF switch was found (p=0.27; fig 2), The longitudinal
improvement in DAS28 was overall more favourable with
rituximab than with an alternative aTNF, irrespective of the
type of TNF switch, despite a suggestion that patients switch-
ing from one anti-TNF monoclonal antibody to another anti-
TNF monoclonal antibody had smaller responses than patients
switching from an anti-TNF monoclonal antibody to a TNF
soluble receptor (DAS28 improvement at 6 months 20.75 (95%
CI 20.42 to 21.09) versus 20.90 (95% CI 20.61 to 21.18),
respectively).
Furthermore, no effect modification appeared to exist
according to the number of previous aTNF failures (p=0.61;
fig 3), indicating that the relative benefit of RTX was similar
after one or several inadequate responses to aTNF. After one
prior aTNF failure, the decrease in DAS28 at 6 months was
21.23 (95% CI 21.46 to 21.00) with RTX and 20.88 (95% CI
21.16 to 20.60) with alternative aTNFs, while after several
aTNF failures, the decrease in DAS28 was 21.31(95% CI 21.53
to 21.10) with RTX and 20.75 (95% CI 21.18 to 20.32) with
alternative aTNFs. We also could not demonstrate significant
effect modification by concomitant DMARD use (p=0.85) or
concomitant methotrexate use (p=0.27). Overall, in 8% of all
patients, doctors reported an AE, with no significant difference
between the two groups (p=0.12). The number of events was
too small to analyse differences in specific AEs between the
groups.
DISCUSSION
This study confirms the results of small observational studies
suggesting that biological agents of a different class, such as
RTX, control RA disease activity more effectively than
a l t e r n a t i v ea T N Fa g e n t si np a t i e n t sw i t ha ni n a d e q u a t e
response to aTNF therapy.
16–19 H o w e v e r ,t h er e l a t i v eb e n e f i t
of RTX varies with the reason for interrupting prior aTNFs
(effect modification). When the motive for switching was
ineffectiveness to an aTNF, the longitudinal improvement in
RA disease activity was significantly more favourable with
R T Xt h a nw i t ha na l t e r n a t i v ea T N Fa g e n t .W h e nt h em o t i v e
for switching was a cause other than ineffectiveness—namely,
an AE or a personal preference, we found no advantage of RTX
compared with a second or third aTNF. Overall, the
magnitude of DAS28 improvements was slightly smaller than
in a pivotal trial of RTX in this indication,
24 which is certainly
related to different study populations and lower disease
activity levels at baseline.
Table 1 Baseline patient and treatment characteristics
Disease characteristics
RTX
(n=155)
Alternative aTNF
(n=163) p Value
Age (years), mean (95% CI) 55 (53 to 57) 55 (53 to 57) 0.70
Gender, male (%) 23 22 0.77
Educational level (years), median (IQR)* 12 (9–12) 12 (9–12) 0.18
RF (%) 88 77 0.02
Disease duration (years), mean (95% CI){ 11.9 (10.5 to 3.2) 10.7 (9.5 to 11.8) 0.18
Disease activity (DAS28), mean (95% CI) 4.99 (4.8 to 5.2) 4.08 (3.9 to 4.3) ,0.001
Functional disability (HAQ), median (IQR){ 1.60 (1.10–2.00) 1.42 (0.96–1.85) 0.03
Concomitant DMARD use1
Methotrexate (%) 67 61 0.20
Leflunomide (%) 17 19 0.72
Other DMARDs (%) 6 3 0.32
None (%) 18 19 0.83
Glucocorticoids (%)" 58 55 0.71
Previous aTNF agents (n), median (IQR) 2 (1–2) 1 (1–1) ,0.001
Single previous aTNF agent (%) 43 88 ,0.001
Two or more previous aTNF agents (%) 57 12 ,0.001
Cause of previous aTNF interruption**
Ineffectiveness (%) 82 51 ,0.001
Adverse events (%) 24 33 0.09
Other (%) 3 18 ,0.001
*Educational level, total number of years of school and college; {disease duration, disease duration at inclusion in years; {HAQ
missing in 89 patients (28%); 1The DMARD percentages represent the use of each co-therapy DMARD at baseline; patients could
receive more than one DMARD co-therapy, which explains why the total may exceed 100%. "Glucocorticoids, concomitant low
dose oral glucocorticoids; **Patients could discontinue aTNF owing to ineffectiveness (primary or secondary aTNF resistance),
owing to adverse events or for other motives (patient preference, pregnancy wish, prolonged travel, etc). The total may exceed
100% because more then one cause could motivate aTNF interruption or different causes might have motivated aTNF
discontinuations when patients had received more then one aTNF that had failed.
aTNF, tumour necrosis factor antagonist; DAS28, 28-joint count Disease Activity Score; DMARD, disease-modifying antirheumatic
drug; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; RTX, rituximab.
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Ann Rheum Dis 2010;69:387–393. doi:10.1136/ard.2008.105064 389Figure 1 Effect modification by prior aTNF ineffectiveness. Change in rheumatoid arthritis (RA) disease activity after initiation of an alternative tumour
necrosis factor antagonist (aTNF) or rituximab (RTX).
The longitudinal improvement in RA disease activity (28-joint count Disease Activity Score (DAS28)) over the average treatment time is represented:
(A) for patients switching because of ineffectiveness to the previous aTNF and (B) for patients switching because of adverse effects to the previous
aTNF or other reasons. The improvement of DAS28 was more favourable with RTX only for patients with a history of prior aTNF ineffectiveness (effect
modification =0.005). The progression trajectories depicted are adjusted for differences in baseline disease characteristics and treatment
characteristics (supplementary appendix). Vertical lines represent the 95% confidence interval of the mean (only lower-bound interval for the RTX
estimates).
Figure 2 Effect modification by the type of aTNF switch. Change in rheumatoid arthritis (RA) disease activity after initiation of an alternative tumour
necrosis factor antagonist (aTNF) versus rituximab (RTX).
The longitudinal improvement in RA disease activity (28-joint count Disease Activity Score (DAS28)) over the average time on treatment is represented:
(A) for patients switching from one aTNF monoclonal antibody (aTNF-AB) to another aTNF-AB; (B) for patients switching from an aTNF soluble receptor
(aTNF-SR) to an aTNF-AB. No significant effect modification existed by the type of aTNF switch (p=0.27). The progression trajectories depicted are
adjusted for differences in baseline disease characteristics and treatment characteristics (supplementary appendix). Vertical lines represent the 95%
confidence interval of the mean (only lower-bound interval for the RTX estimates).
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in RA, it becomes increasingly important to tailor the treatment
to the individual patient in order to maximise the cost–benefit
and to minimise the time for which suboptimal treatments are
given. Patients for whom aTNF fail have different treatment
options, including using a combination of conventional
DMARDs, switching to an alternative aTNF, or changing to
an agent with a different mechanism of action.
71 52 4Available
evidence indicates that switching to a different aTNF agent may
work
10 25; however, several cohort studies have demonstrated
that effectiveness declines and drug retention decreases in
patients who have received one or more TNF inhibitor
previously.
10 26–28
The rationale for introducing agents with a different mode of
action is to overcome problems related to class, particularly in
cases of primary failure or recurrence of class-associated AEs.
The efficacy of other biological agents, such as anakinra (IL1
inhibitor),
29 abatacept (selective costimulation inhibitor),
15 RTX
(B-cell depleting antibodies)
24 or tocilizumab (IL6 signalling
inhibitor)
13 has been confirmed in large placebo-controlled RCTs
in patients with RA with inadequate response to aTNFs.
However, results from existing RCTs are difficult to compare
directly because they involve different patient populations,
study designs and treatment strategies.
30 In the absence of
definitive RCTs comparing ‘‘head-to-head’’ true comparators,
we examined the effect of RTX versus an alternative aTNF in a
cohort study, the next best study design to answer this
question.
31 In our study, the relative benefit of RTX compared
with an alternative aTNF was primarily seen in patients who
had stopped their previous aTNF because of inefficacy, but not
in patients who had stopped their treatment because of AEs or
personal preferences. The relative benefit of RTX compared
with aTNFs appeared already after a single aTNF failure and
was not significantly different after more aTNF failures (fig 3;
p=0.61).
The sequence and type of aTNF switch may further affect the
effectiveness of subsequent aTNF therapies. Some have high-
lighted greater benefits with switching between a soluble
receptor (etanercept) and a monoclonal antibody (infliximab
or adalimumab), compared with switches between monoclonal
antibodies.
32 Our results confirm that patients switching
between an aTNF monoclonal antibody and an aTNF soluble
receptor tend to have slightly larger responses (fig 2), but
longitudinal improvements in DAS28 appear to be overall more
favourable with RTX than with alternative aTNFs, irrespective
of the type of aTNF switch (p=0.27).
Observational studies have intrinsic limitations when analys-
ing the therapeutic effectiveness of different agents. In
particular, selection bias may occur if the assignment to RTX
or an alternative aTNF is not random. In this study, the choice
of the biological agent was strongly associated with preferences
of individual doctors and the year of treatment initiation
(median 2004 for aTNF versus 2006 for RTX) related to
availability. Yet, patients receiving RTX previously had received
significantly more aTNF agents that had failed, had higher
disease activity levels and functional disability at baseline and
were more often RF positive, suggesting that this population
may have a more aggressive disease, which would tend to bias
our results towards the null and result in smaller differences
than in a perfectly balanced setting. We adjusted for these
differences using propensity score stratification, which success-
fully removed observed baseline imbalances. Because baseline
Figure 3 Effect modification by the number of prior aTNF failures. Change in rheumatoid arthritis (RA) disease activity after initiation of an alternative
tumour necrosis factor antagonist (aTNF) versus rituximab (RTX).
The longitudinal improvement in RA disease activity (28-joint count Disease Activity Score (DAS28) over the average time on treatment is represented:
(A) for patients switching after a single prior aTNF failure and (B) for patients switching after multiple prior aTNF failures. No significant effect
modification existed by the type of aTNF switch (p=0.61). The progression trajectories depicted are adjusted for differences in baseline disease
characteristics and treatment characteristics (supplementary appendix).
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exclude the possibility that part of the effect is explained by
residual regression to the mean; however, the relative benefit of
RTX was also seen at lower baseline levels of DAS.
To assess the stability of our approach, we constructed
alternative models using conventional multivariate regression
instead of the propensity score stratification, which yielded very
similar results. Qualitatively similar results were also found
with propensity score adjustments and propensity score
matching, suggesting the results are consistent. While we were
able to control successfully the analysis for potential confound-
ing by these variables, we cannot exclude the possibility of
residual confounding or confounding by unmeasured factors. In
particular, factors such as the time interval between aTNF
discontinuation and new biological initiation (‘‘wash-out
period’’) or the time patients were receiving their last aTNF
were not consistently available for all patients and might have
influenced the results if different between the two groups.
Another concern with observational studies is missing data.
Our inclusion criteria permitted analysis of 66% of all patients
receiving a second biological agent in the SCQM-RA cohort.
Baseline disease characteristics of excluded patients were similar
to those included in the analysis (data not shown), suggesting
that our inclusion criteria gathered a representative sample of
the population. Finally, it is difficult to establish whether the
biological agents were used optimally. In this analysis, RTX was
censored at the time of re-treatment, but in certain instances,
patients might have benefited from earlier re-treatment. For
aTNF, some patients might have been helped by higher dosages
or shorter administration intervals. However, the data represent
‘‘real-world’’ patients and realistic clinical practice.
6
In conclusion, these results suggest that a biological agent
with a different mechanism of action, such as RTX, is an
effective therapeutic alternative for patients who stopped a
previous aTNF treatment owing to its ineffectiveness.
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